| Symbol | NXTC |
|---|---|
| Name | NEXTCURE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9000 VIRGINIA MANOR ROAD,SUITE 200, BELTSVILLE, Maryland, 20705, United States |
| Telephone | +1 240 - 399-4900 |
| Fax | — |
| — | |
| Website | https://www.nextcure.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001661059 |
| Description | NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The companys product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15. Additional info from NASDAQ: |
2026-06-04 12:00
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
Read more
2026-06-01 12:00
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
Read more
2026-05-13 17:42
New Form SCHEDULE 13G/A - NextCure, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001104659-26-060317 <b>Size:</b> 8 KB
Read more
2026-05-07 20:05
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
Read more
2026-05-06 22:27
New Form SCHEDULE 13G/A - NextCure, Inc. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001213900-26-052993 <b>Size:</b> 20 KB
Read more
2026-05-04 11:05
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Read more
2026-04-24 17:19
New Form DEFA14A - NextCure, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048606 <b>Size:</b> 383 KB
Read more
2026-04-24 17:16
New Form DEF 14A - NextCure, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048591 <b>Size:</b> 4 MB
Read more
2026-04-21 14:15
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab i… | Phase2 | Pancreatic Cancer | Recruiting | 2025-09-04 | 2028-12-01 | ClinicalTrials.gov |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Recruiting | 2025-02-26 | 2028-08-01 | ClinicalTrials.gov |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase1 | Ovarian Cancer | Recruiting | 2025-01-07 | 2026-12-01 | ClinicalTrials.gov |
| NCT05787496 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced My… | Phase1 | Relapsed or Refractory Acute Myeloid Leukemia | Terminated | 2023-02-28 | 2025-01-31 | ClinicalTrials.gov |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Partic… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2022-10-06 | 2025-11-01 | ClinicalTrials.gov |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for S… | Phase1 | Advanced or Metastatic Solid Tumors | Withdrawn | 2021-12-06 | 2022-10-30 | ClinicalTrials.gov |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastati… | Phase1 | Advanced or Metastatic Solid Tumors | Terminated | 2021-06-30 | 2024-01-30 | ClinicalTrials.gov |
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With … | Phase2 | Advanced Non-small Cell Lung Cancer | Active_Not_Recruiting | 2021-02-04 | 2025-06-30 | ClinicalTrials.gov |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastati… | Phase1 | Advanced or Metastatic Solid Tumors | Terminated | 2020-06-10 | 2023-07-06 | ClinicalTrials.gov |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastati… | Phase1 | Advanced or Metastatic Solid Tumors | Completed | 2018-10-01 | 2023-04-11 | ClinicalTrials.gov |
Total clinical trials: 10
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC762 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | TERMINATED | NCT04875806 |
| Docetaxel | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| Nab paclitaxel/Carboplatin | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| Pemetrexed/Carboplatin | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| NC318 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| NC318 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | COMPLETED | NCT03665285 |
| NC410 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | TERMINATED | NCT04408599 |
| pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05572684 |
| NC410 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05572684 |
| Pembrolizumab | Other | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| NC318 400 mg | Other | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| NC318 800 mg | Other | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| LNCB74 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06774963 |
| NC525 | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT05787496 |
| Ipilimumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC410 | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| SIM0505 for injection | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06792552 |
| Ipilimumab | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Nivolumab | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| 5-Fluorouracil (5-FU) | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Folinic Acid | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Irinotecan | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| Oxaliplatin | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| SIM0505 for injection | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06792552 |
| LNCB74 | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06774963 |
| NC525 | DRUG | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | TERMINATED | NCT05787496 |
| pembrolizumab | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05572684 |
| NC762 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | TERMINATED | NCT04875806 |
| Pembrolizumab | DRUG | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| NC318 400 mg | DRUG | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| NC318 800 mg | DRUG | Phase PHASE2 | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04699123 |
| Docetaxel | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| Nab paclitaxel/Carboplatin | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| Pemetrexed/Carboplatin | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
| NC410 | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT06941857 |
| NC318 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | WITHDRAWN | NCT04430933 |
Total products: 160